A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma

耐受性 医学 内科学 中性粒细胞减少症 外周T细胞淋巴瘤 胃肠病学 不利影响 淋巴瘤 耐火材料(行星科学) 临床研究阶段 外科 化疗 T细胞 免疫学 免疫系统 物理 天体生物学
作者
Jie Jin,Hong Cen,Keshu Zhou,Xiaohong Xu,Fei Li,Tao Wu,Haiyan Yang,Zhen Wang,Zhiming Li,Wenyang Huang,Hanying Bao,Zusheng Xu,Lugui Qiu
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:30 (20): 4593-4600 被引量:10
标识
DOI:10.1158/1078-0432.ccr-24-1194
摘要

Abstract Purpose: Relapsed and/or refractory peripheral T-cell lymphoma (r/r PTCL) is an aggressive and heterogeneous hematologic malignancy with high unmet need. Previously, PI3K inhibitors were shown to be efficacious in B- and T-cell lymphomas, but as a drug class, these agents have frequently been observed to have tolerability limitations. Next-generation agents that improve the tolerability while maintaining efficacy are desirable. Patients and Methods: A phase Ib clinical study was conducted with the oral PI3K-delta isoform-selective small-molecule inhibitor, linperlisib, in patients with r/r PTCL, and the clinical benefit was explored by the evaluation of safety and efficacy. Results: In this clinical study, 43 patients with r/r PTCL in China were treated with continuous dosing of 80-mg linperlisib once a day. Treatment-related adverse events (AE) were manageable. The most frequently reported grade 3 AE were neutropenia (21%), pneumonia (11.6%), and hypertriglyceridemia (7%). All other AE were either absent or reported in <5% of the patients. Linperlisib treatment for these patients with r/r PTCL, consisting of the major PTCL subtypes, was observed to have a 60.5% overall response rate with 35% complete responses and led to a median duration of response of 11.1 months, median progression-free survival of 11.8 months, and a median overall survival of >38 months (not reached). Conclusions: With the very promising clinical activity against r/r PTCL, the results of this study support the further investigation of linperlisib for the treatment of r/r PTCL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
张升起发布了新的文献求助10
刚刚
刚刚
在水一方应助我到了啊采纳,获得10
1秒前
俏皮听寒完成签到,获得积分10
1秒前
1秒前
1秒前
123发布了新的文献求助10
2秒前
卡卡发布了新的文献求助10
2秒前
洋葱头小姐完成签到 ,获得积分10
2秒前
2秒前
1121完成签到,获得积分10
3秒前
Simone完成签到,获得积分10
3秒前
3秒前
Yy发布了新的文献求助10
4秒前
开心雨旋完成签到,获得积分10
4秒前
今后应助嗯qq采纳,获得10
4秒前
wanci应助邱锡雨采纳,获得10
5秒前
crow完成签到,获得积分10
5秒前
6秒前
Simone发布了新的文献求助10
6秒前
柏小霜发布了新的文献求助10
6秒前
阳光书白发布了新的文献求助30
7秒前
辰勃发布了新的文献求助30
7秒前
7秒前
7秒前
8秒前
小太阳完成签到 ,获得积分10
8秒前
一颗松应助wys2493采纳,获得10
9秒前
打打应助jhy0803采纳,获得10
9秒前
SciGPT应助卡卡采纳,获得10
9秒前
zhangguo发布了新的文献求助10
10秒前
10秒前
10秒前
10秒前
11秒前
捏个小雪团完成签到 ,获得积分10
11秒前
wenhao发布了新的文献求助10
12秒前
Anonymous发布了新的文献求助10
13秒前
zuozuo发布了新的文献求助10
13秒前
kunkun完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Relation between chemical structure and local anesthetic action: tertiary alkylamine derivatives of diphenylhydantoin 1000
Signals, Systems, and Signal Processing 610
Discrete-Time Signals and Systems 610
Principles of town planning : translating concepts to applications 500
Iron‐Sulfur Clusters: Biogenesis and Biochemistry 400
Healable Polymer Systems: Fundamentals, Synthesis and Applications 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 物理 生物化学 化学工程 计算机科学 复合材料 内科学 催化作用 光电子学 物理化学 电极 冶金 遗传学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 6070953
求助须知:如何正确求助?哪些是违规求助? 7902535
关于积分的说明 16338667
捐赠科研通 5211577
什么是DOI,文献DOI怎么找? 2787372
邀请新用户注册赠送积分活动 1770167
关于科研通互助平台的介绍 1648118